Online inquiry

IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10828MR)

This product GTTS-WQ10828MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets PD-L1; TGFBR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2; NM_001024847.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126; 7048
UniProt ID Q9NZQ7; P37173
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10828MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11513MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ4537MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ8577MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ10638MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ14555MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ13916MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ5432MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ824MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-085
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW